Belluscura Logo

Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
(“Belluscura” or the “Company” or “Group”)

Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)

X-PLO2R™ portable oxygen concentrator now covered by two Medicare reimbursement codes

LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Medicare Administrative Contractor Palmetto GBA MolDx (“Palmetto”) has issued a final local coverage determination for the X-PLO2R™ portable oxygen concentrator (“X-PLO2R”). Weighing only 3.25 lbs (1.5kg), the X-PLO2R is the world’s first portable modular oxygen concentrator.

Medicare reimbursement covers approximately 50% of the oxygen concentrator market in the US. The Board believes the approval of the two reimbursement codes will have a positive impact on the Company and expects to update shareholders on the full-year outcome for FY21 in early January 2022.

Robert Rauker, CEO of Belluscura plc, commented: “Receiving the two Medicare reimbursement codes should further expand access and the use and distribution of the X-PLO2R throughout the US. We believe many Medicare patients will ask their health care providers and durable medical equipment providers to issue them with the lightweight X-PLO2R.”

For further information please contact:

Belluscura plc www.belluscura.com

Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin

Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers

Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers, and insurance organizations.